SPAP prolonged until the end of 2027

We are pleased to announce that, on the initiative of SSMO, all current partner companies have agreed to an prolongation of the Swiss Patient Access Program (SPAP). This important program will therefore continue, probably until the end of 2027.

As a reminder, SPAP was launched by SSMO to give cancer patients rapid and equal access to off-label use medicines that had previously been rejected twice by health insurance companies. You are welcome to submit your applications to SPAP here.

SPAP in the news: The Tages-Anzeiger published an article on SPAP on 7 October 2025. You can read the article here.